POS0983 WORK PARTICIPATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN GERMANY: RESULTS FROM A MULTICENTER, OBSERVATIONAL SURVEY (ATTENTUS-axSpA)

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation 1 not only translating to devastating outcomes for patients (pts) but also increased economic and social burden due significant amount of indirect costs. Data on the different work domains in axSpA pts access biologic therapies are limited. Objectives: To characterise [presenteeism, absenteeism, sick leave, unemployment, disability pensions] their associations demographic clinical confounders. Methods: Pts confirmed diagnosis were enrolled multicenter, observational ATTENTUS survey conducted across Germany (Nov-2019 Jul-2020). ensure high data quality, inclusion criteria was verified by external monitoring, followed evaluation participation, including absenteeism presenteeism (WPAI). Demographics, parameters patient related (PROs) collected via tablet. This analysis included age (18–65 years) pts; excluded students retired pts. without (value=0) ≤20% defined as no impairment at work. Results: A total 787 survey. Seven students, 68 17 fulfilling from this analysis, leaving 695 complete sets. Baseline outlined Table 1. 50 received pensions, 29 unemployment benefits, 590 (84.9%) reported paid [part-time: n=132 (22.4%); full-time: n=458 (65.9%)], 242 (41.0%) having impairments 379 (64.2%) employed took leave within previous 12 months (mo) (<3 mo: n=351; 3–6 n=17; >6 n=11). Absenteeism occurred 140 (23.7%) 496 (84.1%) pts, respectively. mostly young age, male sex, well-educated, low disease activity, less fatigue shorter duration morning stiffness, preserved global physical functioning. No apparent differences between observed terms treatment, BMI. Descriptive characteristics study population Mean (SD), unless specified Impaired WP (n=453 ) Full (n=242 p-value Total (n=695 Age (yrs) 46.7 (11.1) 42.8 (10.1) <0.001 45.3 (10.9) BMI 28.5 (14.0) 27.0 (6.8) 0.146 28.0 (12.0) Male, n(%) 246 (54) 177 (73) 423 (61) Disease 12.7 (11.3) 12.4 (10.2) 0.813 12.6 (11.0) University-Education, 104 (23.0) 82 (33.9) 0.001 186 (26.8) In committed relation, 310 (68.4) 159 (65.7) 0.464 469 (6.6) ASAS-HI 8.0 (3.3) 3.7 (3.0) 6.5 (3.8) BASDAI 4.8 (1.9) 2.1 (1.6) 3.9 (2.2) > 4, 286 (63.1) 28 (11.6) 314 (45.2) Fatigue [BASDAI #1] 5.8 (2.1) 2.8 4.7 (2.5) Duration stiffness #6] 3.5 (2.4) 1.6 (1.8) BASFI 4.2 (2.3) 1.5 (1.5) 3.3 Biologic 230 (50.8) 134 (55.4) 0.390 364 (52.4) time employment, 256 (56.5) 202 (83.5) 458 (65.9) 17.9 (32.1) 0 - 10.6 (26.2) Presenteeism 48.6 (21.00) 9.6 (8.3) 32.6 (25.6) ASAS-HI, Assessment SpondyloArthritis International Society-Health Index; BASDAI, Bath Ankylosing Spondylitis Activity BASFI, Functional BMI, basal metabolic index; n, number SD, standard deviation; WP, productivity; years, yrs Conclusion: There substantial impact despite numerous available therapeutic options. compared impairment, fatigue, longer decreased functional capacity, female sex lower level education. References: [1]Ramoda R et al. Arthritis Res Ther . 2016;78 Disclosure Interests: Uta Kiltz Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche UCB, Consultant of: Grant/research support from: Abbvie, Amgen, Biogen, Fresenius, GSK, Novartis Kirsten Hoeper Gilead, Sandoz Hexal Sanofi. Ludwig Hammel: None declared, Sebastian Lieb Employee Andreas Haehle Dirk Meyer-Olson Berlin Chemie, Bristol Myers Squibb, Cellgene, Fresenius Kabi, Jansen Cilag, Medac, Merck Sharp & Dome, Mylan, Hexal, Sanofi UCB.